Registration of medicines (click here)
Registration of medicines (click here)
Note: To determine documents according to HS code, follow the link, open the "Calculator" ("Калькулятор") tab, enter HS code, open the "Documents" ("Документы") tab below.
SI «The Center for Pharmaceutical Products Safety» under the Ministry of Health of the Republic of Uzbekistan (hereinafter referred to as the State Center) — is a working body of the Pharmaceutical Industry Development Agency, which ensures the implementation of state registration, quality control, standardization and certification of medicines, medical devices и medical equipment.
Subject to registration are:
The following are not required to be registered:
Substances used for the manufacture of medicines, medicines intended for export may be registered at the request of the applicant.
Medical devices intended for export may be registered at the request of the applicant.
It is not allowed to register medicines containing different medicinal substances under the same trade name. It is allowed to register medicines containing the same medicinal substances, which are produced by the same manufacturer under different trade names on the basis of contract and technology transfer. In this case, the certificate holder may be the client or the technology transfer holder.
Orphan medicines, imported medicines and medical devices used in the prevention, diagnosis and treatment of epidemiologically dangerous infections, as well as infections posing an epidemiological danger, as ordered by the Ministry of Health of the Republic of Uzbekistan, may be imported without state registration.
Medicines and medical devices imported as foreign aid and humanitarian assistance are allowed to be imported into and used in the territory of the Republic of Uzbekistan without state registration. In this case, the Ministry of Health of the Republic of Uzbekistan shall issue a positive opinion on the import into and use of these medicines and medical devices in the territory of the Republic of Uzbekistan.
A certificate of compliance with the national requirements of the Republic of Uzbekistan for «Good Manufacturing Practices (GMP)» is required for state registration of medicines and for extending the validity period of the certificate of registration.
Medicines produced during the validity period of the registration certificate and whose registration certificate has expired shall be allowed to undergo quality control, be imported and sold for 180 calendar days after the expiration of the certificate of registration, and be used in medical practice until the expiration date. In this case, the quality control of medicines shall be carried out in accordance with the requirements of documents approved during the validity period of the certificate.
The validity period of the certificate may be extended upon application submitted by the applicant to the Center through the information system. An application for extension of the validity period of the certificate must be submitted to the Center within nine months before its expiration date. Extension of the validity period of the certificate shall be in accordance with the procedure established for registration.
During the extension of the validity period of the certificate for a medicine, no laboratory tests shall be conducted unless amendments are made to the registration documents related to manufacturing processes, including the manufacturer of the active substance, the composition of excipients, packaging, quality control methods, standards, and production technology. In this case, the quality of medicines whose validity period has been extended without laboratory tests shall be subject to mandatory post-marketing control.
In the process of state registration of medical devices, the quality system of their production conditions shall be inspected for compliance with the requirements of the national standard of the Republic of Uzbekistan, harmonized with the international standard «ISO 13485», with the exception of medical devices registered under the recognition principle and in vitro diagnostic medical devices requalified (prequalified) by the WHO, and registered jointly with the WHO.
In this case, it is allowed to conduct the inspection of the manufacturer’s production conditions for compliance with the requirements of the national standard of the Republic of Uzbekistan, harmonized with the international standard «ISO 13485», simultaneously with the state registration process of the medical device. In this case, a certificate of compliance with the requirements of the national «ISO 13485» standard must be submitted before the medical device is registered by the Center.
Based on the results of registration of medicines, medical devices and medical equipment, a certificate valid for 5 years is issued.
The State Center is responsible for the disclosure of confidential information contained in registration documents.
After the validity period of the certificate, it is allowed to sell the medical devices and use it in medical practice, if they were produced during the validity period of the registration certificate.
The State Center maintains a register of issued certificates and posts it on its official website.
The information contained in the register of issued certificates is open to review by legal entities and individuals.
Medicines produced on the basis of cell technology, or cell-based therapies/biopharmaceuticals, are specialized treatments derived from living cells — such as stem cells, immune cells, or engineered mammalian/yeast cells — that either directly repair damaged tissue or manufacture complex proteins. These, including monoclonal antibodies and stem cell therapies, are used to treat diseases like cancer, diabetes, and genetic disorders.
In vitro diagnostic (IVD) medical devices are reagents, instruments, and systems intended to examine samples derived from the human body — such as blood, urine, or tissue — outside the body. They are used to diagnose diseases, monitor health conditions, or screen for infections, providing critical information for treatment without contacting the patient.
Orphan medicines are specialized pharmaceutical products developed specifically to diagnose, prevent, or treat rare diseases and conditions that affect small patient populations. Due to the low number of patients, these drugs would not be developed under normal market conditions, prompting governments to offer incentives like tax credits and market exclusivity to encourage their creation.